Unraveling Antiseizure Medication Adherence in Paediatric Epilepsy: Implications for Clinical Practice and Patient

Anchu Anna Cherian1, Mini Sreedharan1, Priya Sreenivasan2

  • 1Department of Pediatric Neurology, Government Medical College Thiruvananthapuram, India.

Epilepsy & Behavior : E&B
|October 30, 2024
PubMed

Insights

In children with epilepsy, 32% showed non-adherence to antiseizure medications. Addressing medication side effects and patient beliefs is crucial for improving adherence in pediatric epilepsy management.

Area of Science:

  • Pediatric Neurology
  • Epilepsy Management
  • Medication Adherence Research

Background:

  • Non-adherence to antiseizure medications (ASM) is a significant, modifiable risk factor for poor epilepsy control in children.
  • It contributes to increased hospitalizations, biased treatment effectiveness assessments, and flawed clinical decision-making.

Purpose of the Study:

  • To determine the proportion of non-adherence to ASM among children with epilepsy.
  • To identify clinical and demographic factors associated with ASM non-adherence in this population.

Main Methods:

  • A study involving children (≤18 years) with epilepsy on ASM for at least three months was conducted.
  • Self-reported adherence was measured using the Medication Adherence Report Scale, and beliefs about medications were assessed.
  • Clinicodemographic factors and medication beliefs were analyzed for their association with non-adherence.

Main Results:

  • The rate of non-adherence to ASM in children with epilepsy was found to be 32%.
  • Significant associations with non-adherence included ASM side effects (OR: 3.01) and ASM Concerns (OR: 0.84), as well as the Necessity-Concern Differential Score (OR: 1.19).
  • Multivariate analysis confirmed the significance of both ASM side effects and ASM beliefs (NCD score) in relation to adherence.

Conclusions:

  • Medication perceptions significantly and modifiably influence non-adherence in pediatric epilepsy.
  • Interventions should be individualized, addressing patient/family beliefs and practical barriers like medication side effects to enhance adherence.
Abstract

Related Concept Videos

Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
437
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
147
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
330
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
258
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
285